Go Therapeutics Inc.首席执行官君士坦丁Theodoropulos首次进入糖蛋白质组学领域,特别是被截短的O-聚糖作为癌症靶标的潜力时说,同龄人的反应并不令人鼓舞。“They said, ‘You’re nuts, it’s too complicated.’” Now, however, the company he co-founded has landed a deal with Astellas Pharma Inc.’s immuno-oncology-focused subsidiary, Xyphos Biosciences Inc., that brings $20.5 million up front, with the potential for up to $763 million in milestone and contingency payments down the road.